Supreme Court tosses Bristol Myers' bid to revive $1.2B CAR-T case against Gilead
In the latest setback for Bristol Myers Squibb in a years-long legal tussle with Gilead over a CAR-T patent, the Supreme Court of the United States has declined to hear its petition to revive a $1.2 billion verdict.
At its core, Bristol Myers claimed that Gilead’s pioneering CAR-T, Yescarta, infringed on its patent relating to the composition of a chimeric antigen receptor — the CAR in CAR-T — that can be genetically engineered into a T cell.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.